

Global epidemiology of NAFLD-related HCC: trends, prevention

Nature Reviews Gastroenterology and Hepatology

18, 223-238

DOI: [10.1038/s41575-020-00381-6](https://doi.org/10.1038/s41575-020-00381-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?. <i>Liver Cancer</i> , 2021, 10, 289-295.	4.2	6
2	Exercise-Mediated Autophagy and Nonalcoholic Fatty Liver Disease. , 2021, , 81-101.		0
3	Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 730.	1.7	35
4	Hepatic Senescence Accompanies the Development of NAFLD in Non-Aged Mice Independently of Obesity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3446.	1.8	19
5	The Consumption of Cholesterol-Enriched Diets Conditions the Development of a Subtype of HCC with High Aggressiveness and Poor Prognosis. <i>Cancers</i> , 2021, 13, 1721.	1.7	13
6	Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. <i>Advances in Therapy</i> , 2021, 38, 2130-2158.	1.3	46
7	The Liver and the Cardiovascular System: Two of a Kind?. <i>Journal of the American Heart Association</i> , 2021, 10, e020286.	1.6	6
8	Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4495.	1.8	56
9	Fatty liver progression and carcinogenesis: Beware of pathogenic TÁcells. <i>Med</i> , 2021, 2, 453-455.	2.2	2
10	Clinical characteristics and longitudinal changes of patients with non-alcoholic fatty liver disease in 2Ádecades: the NAGALA study. <i>BMC Gastroenterology</i> , 2021, 21, 223.	0.8	4
11	One Week of CDAHFD Induces Steatohepatitis and Mitochondrial Dysfunction with Oxidative Stress in Liver. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5851.	1.8	14
12	Liver macrophages and inflammation in physiology and physiopathology of nonÁalcoholic fatty liver disease. <i>FEBS Journal</i> , 2022, 289, 3024-3057.	2.2	37
13	Understanding the Role of Perilipin 5 in Non-Alcoholic Fatty Liver Disease and Its Role in Hepatocellular Carcinoma: A Review of Novel Insights. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5284.	1.8	15
14	Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 2305.	1.7	24
15	High glucose induced c-Met activation promotes aggressive phenotype and regulates expression of glucose metabolism genes in HCC cells. <i>Scientific Reports</i> , 2021, 11, 11376.	1.6	6
16	Research progress on intervention effect and mechanism of protocatechuic acid on nonalcoholic fatty liver disease. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 9053-9075.	5.4	14
17	Autophagy in liver diseases: A review. <i>Molecular Aspects of Medicine</i> , 2021, 82, 100973.	2.7	136
18	LncRNA MAYA promotes iron overload and hepatocyte senescence through inhibition of YAP in nonÁalcoholic fatty liver disease. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 7354-7366.	1.6	20

#	ARTICLE	IF	CITATIONS
20	An engineered mayhem: YAP/TAZ mechanosignaling and hepatocarcinogenesis in NAFLD. Exploration of Medicine, 0, .	1.5	0
21	Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers, 2021, 13, 3473.	1.7	12
22	Risk for hepatic and extrahepatic outcomes in nonalcoholic fatty liver disease. Journal of Internal Medicine, 2022, 292, 177-189.	2.7	11
23	A study of 3013 cases of hepatocellular carcinoma: Etiology and therapy before and during the current decade. JGH Open, 2021, 5, 1015-1018.	0.7	4
24	Lupinus angustifolius Protein Hydrolysates Reduce Abdominal Adiposity and Ameliorate Metabolic Associated Fatty Liver Disease (MAFLD) in Western Diet Fed-ApoE ^{-/-} Mice. Antioxidants, 2021, 10, 1222.	2.2	16
25	Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Clinical Patterns, Outcomes, and Prognostic Factors for Overall Survival—A Retrospective Analysis of a Slovak Cohort. Journal of Clinical Medicine, 2021, 10, 3186.	1.0	2
27	MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. Hepatology Research, 2021, 51, 1115-1128.	1.8	104
28	Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD). Medical Science Monitor, 2021, 27, e933860.	0.5	8
29	Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Seminars in Liver Disease, 2021, 41, 421-434.	1.8	55
31	Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. Cureus, 2021, 13, e17321.	0.2	3
32	Pharmacological benefits of <i>Acacia</i> against metabolic diseases: intestinal-level bioactivities and favorable modulation of gut microbiota. Archives of Physiology and Biochemistry, 2024, 130, 70-86.	1.0	5
33	Synthesis of digestive enzymes, food processing, and nutrient absorption in decapod crustaceans: a comparison to the mammalian model of digestion. Zoology, 2021, 147, 125945.	0.6	27
34	Diagnostic Accuracy of FIB-4 and FIB-5 Scores as Compared to Fibroscan for Assessment of Liver Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease. Cureus, 2021, 13, e17622.	0.2	1
35	NAFLD and HCC: Time to Bridge the Gap. Hepatology, 2021, 74, 2336-2338.	3.6	3
36	Editorial: aspirin and NSAID for chemoprevention of hepatocellular carcinoma—ready for their use?. Alimentary Pharmacology and Therapeutics, 2021, 54, 850-851.	1.9	4
37	Genetic predisposition, lifestyle risk, and obesity associate with the progression of nonalcoholic fatty liver disease. Digestive and Liver Disease, 2021, 53, 1435-1442.	0.4	13
38	DNA Methylation of TGF β 2 Target Genes: Epigenetic Control of TGF β 2 Functional Duality in Liver Cancer. Cells, 2021, 10, 2207.	1.8	7
39	Lack of response to immunotherapy in non-alcoholic steatohepatitis related hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2021, 10, 522-525.	0.7	9

#	ARTICLE	IF	CITATIONS
40	Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 174-179.	0.4	2
41	NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. <i>Cells</i> , 2021, 10, 2034.	1.8	20
42	Perilipin 5 Ameliorates Hepatic Stellate Cell Activation via SMAD2/3 and SNAIL Signaling Pathways and Suppresses STAT3 Activation. <i>Cells</i> , 2021, 10, 2184.	1.8	8
43	Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 880-889.	1.9	51
44	Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 4567.	1.7	8
45	Ethanol Extract of <i>Liriope platyphylla</i> Root Attenuates Non-Alcoholic Fatty Liver Disease in High-Fat Diet-Induced Obese Mice via Regulation of Lipogenesis and Lipid Uptake. <i>Nutrients</i> , 2021, 13, 3338.	1.7	10
46	Rational HCC screening approaches for patients with NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 195-201.	1.8	47
47	Dihydromyricetin attenuates palmitic acid-induced oxidative stress by promoting autophagy via SIRT3-ATG4B signaling in hepatocytes. <i>Nutrition and Metabolism</i> , 2021, 18, 83.	1.3	11
48	Beyond the X Factor: Relevance of Sex Hormones in NAFLD Pathophysiology. <i>Cells</i> , 2021, 10, 2502.	1.8	28
49	Lipid-Lowering Bioactivity of Microalga <i>Nitzschia laevis</i> Extract Containing Fucoxanthin in Murine Model and Carcinomic Hepatocytes. <i>Pharmaceuticals</i> , 2021, 14, 1004.	1.7	3
50	Pulmonary hypertension is associated with an increased incidence of NAFLD: A retrospective cohort study of 18,910 patients. <i>Journal of Internal Medicine</i> , 2021, 290, 886-893.	2.7	7
51	CELSR2 deficiency suppresses lipid accumulation in hepatocyte by impairing the UPR and elevating ROS level. <i>FASEB Journal</i> , 2021, 35, e21908.	0.2	8
52	Nonalcoholic steatohepatitis: global impact and clinical consequences. <i>Endocrine Connections</i> , 2021, 10, R240-R247.	0.8	18
53	Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1253-1266.	1.4	9
54	NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. <i>Journal of Hepatology</i> , 2022, 76, 446-457.	1.8	121
55	Methyl Brevifolincarboxylate Attenuates Free Fatty Acid-Induced Lipid Metabolism and Inflammation in Hepatocytes through AMPK/NF- κ B Signaling Pathway. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10062.	1.8	8
56	Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. <i>World Journal of Hepatology</i> , 2021, 13, 1107-1121.	0.8	4
57	Clinical Relevance of Selenium with Liver Stiffness and Steatosis Detected by Transient Elastography in Adults. <i>Biological Trace Element Research</i> , 2022, 200, 3041-3049.	1.9	5

#	ARTICLE	IF	CITATIONS
58	Combined Transcriptomic and Lipidomic Analysis Reveals Dysregulated Genes Expression and Lipid Metabolism Profiles in the Early Stage of Fatty Liver Disease in Rats. <i>Frontiers in Nutrition</i> , 2021, 8, 733197.	1.6	3
59	A novel quantitative ultrasound technique for identifying non-alcoholic steatohepatitis. <i>Liver International</i> , 2022, 42, 80-91.	1.9	6
60	Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice. <i>Hepatology</i> , 2022, 75, 140-153.	3.6	30
61	Non-alcoholic fatty liver disease: A patient guideline. <i>JHEP Reports</i> , 2021, 3, 100322.	2.6	109
62	Trimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 733507.	1.6	25
63	Hepatic Regulator of G Protein Signaling 6 (RGS6) drives non-alcoholic fatty liver disease by promoting oxidative stress and ATM-dependent cell death. <i>Redox Biology</i> , 2021, 46, 102105.	3.9	17
64	A double-edged sword: The Kelch-like ECH-associated protein 1-nuclear factor erythroid-derived 2-related factor 2-antioxidant response element pathway targeted pharmacological modulation in nonalcoholic fatty liver disease. <i>Current Opinion in Pharmacology</i> , 2021, 60, 281-290.	1.7	4
65	Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2021, 75, 865-878.	1.8	111
66	The paradox role of cytotoxic T-lymphocytes in NAFLD-associated hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 705-707.	0.7	4
68	The Localization of NEK6 in HepG2 Cell Line and Its Expression and Clinical Significance in HCC. <i>World Journal of Cancer Research</i> , 2021, 11, 67-75.	0.1	0
69	Switch-associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1. <i>Hepatology</i> , 2022, 75, 1507-1522.	3.6	10
70	Flaxseed Powder Attenuates Non-Alcoholic Steatohepatitis via Modulation of Gut Microbiota and Bile Acid Metabolism through Gut-Liver Axis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10858.	1.8	15
71	Clinical relevance of environmental manganese exposure with liver stiffness and steatosis detected by transient elastography in adults. <i>Environmental Science and Pollution Research</i> , 2022, 29, 16624-16632.	2.7	5
72	Current epidemiology in hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1295-1307.	1.4	107
73	Combined Metabolic Activators Decrease Liver Steatosis by Activating Mitochondrial Metabolism in Hamsters Fed with a High-Fat Diet. <i>Biomedicines</i> , 2021, 9, 1440.	1.4	8
74	Astaxanthin attenuates hepatic steatosis in high-fat diet-fed rats by suppressing microRNA-21 via transactivation of nuclear factor erythroid 2-related factor 2. <i>Journal of Physiology and Biochemistry</i> , 2022, 78, 151-168.	1.3	14
75	Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. <i>Journal of Hepatology</i> , 2022, 76, 265-274.	1.8	24
76	Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. <i>Biomedicines</i> , 2021, 9, 1524.	1.4	10

#	ARTICLE	IF	CITATIONS
77	Exercise prevents fatty liver by modifying the compensatory response of mitochondrial metabolism to excess substrate availability. <i>Molecular Metabolism</i> , 2021, 54, 101359.	3.0	11
79	A network-based approach reveals the dysregulated transcriptional regulation in non-alcoholic fatty liver disease. <i>IScience</i> , 2021, 24, 103222.	1.9	14
80	Loss of Hepatic Transcription Factor EB Attenuates Alcohol-Associated Liver Carcinogenesis. <i>American Journal of Pathology</i> , 2022, 192, 87-103.	1.9	9
81	Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. <i>Frontiers in Endocrinology</i> , 2021, 12, 760860.	1.5	33
82	Advances in RNA Epigenetic Modifications in Hepatocellular Carcinoma and Potential Targeted Intervention Strategies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 777007.	1.8	9
83	Bioinformatics Analysis Explores Potential Hub Genes in Nonalcoholic Fatty Liver Disease. <i>Frontiers in Genetics</i> , 2021, 12, 772487.	1.1	14
84	Nonalcoholic fatty liver disease-related hepatocellular carcinoma growth rates and their clinical outcomes. , 2021, 7, .		4
85	Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2022, 126, 154925.	1.5	134
86	Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. <i>Frontiers in Microbiology</i> , 2021, 12, 761836.	1.5	21
87	Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank. <i>International Journal of Obesity</i> , 2022, 46, 486-493.	1.6	12
88	Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00420.	1.3	6
89	Vitamin D3 supplementation alleviates chemically-induced cirrhosis-associated hepatocarcinogenesis. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2022, 215, 106022.	1.2	6
90	The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 792667.	1.6	11
91	Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for <i>Clostridioides difficile</i> infection. <i>World Journal of Hepatology</i> , 2021, 13, 1777-1790.	0.8	2
92	Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 45-54.e6.	2.4	29
93	Therapeutic Targeting of Nonalcoholic Fatty Liver Disease by Downregulating SREBP-1C Expression via AMPK-KLF10 Axis. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 751938.	1.6	12
94	Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. <i>Cancers</i> , 2021, 13, 5844.	1.7	27
95	Changes in therapeutic options for hepatocellular carcinoma in Asia. <i>Liver International</i> , 2022, 42, 2055-2066.	1.9	14

#	ARTICLE	IF	CITATIONS
96	A nanodrug system overexpressed circRNA_0001805 alleviates nonalcoholic fatty liver disease via miR-106a-5p/miR-320a and ABCA1/CPT1 axis. <i>Journal of Nanobiotechnology</i> , 2021, 19, 363.	4.2	20
97	Role of Main RNA Methylation in Hepatocellular Carcinoma: N6-Methyladenosine, 5-Methylcytosine, and N1-Methyladenosine. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 767668.	1.8	26
98	Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. <i>Nature Reviews Endocrinology</i> , 2022, 18, 55-66.	4.3	82
99	Caffeine and EGCG Alleviate High-Trans Fatty Acid and High-Carbohydrate Diet-Induced NASH in Mice: Commonality and Specificity. <i>Frontiers in Nutrition</i> , 2021, 8, 784354.	1.6	9
100	MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 150-163.	4.5	53
101	Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study. <i>Endoscopy International Open</i> , 2021, 09, E1792-E1800.	0.9	5
102	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, 38, 261-267.	0.8	2
103	The EASL "Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , 2022, 399, 61-116.	6.3	257
104	In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications. <i>IScience</i> , 2022, 25, 103549.	1.9	44
105	An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 619-629.e7.	2.4	90
106	The association between NAFLD and risk of chronic kidney disease: a cross-sectional study. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110486.	1.1	17
107	Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 78-93.	0.7	24
108	NAFLD in type 1 diabetes: overrated or underappreciated?. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110555.	1.4	14
109	De novo lipogenesis in non-alcoholic fatty liver disease: Quantification with stable isotope tracers. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13733.	1.7	8
110	Rubicon in Metabolic Diseases and Ageing. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 816829.	1.8	5
111	Immunotherapy in older patients with hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2022, 162, 76-98.	1.3	8
112	Verbascoside, a Caffeoyl Phenylethanoid Glycoside Mediates the Prophylactic Role of <i>Premna Herbacea</i> , a Dietary Leafy Vegetable in Managing Hepatic Steatosis Via Regulating AMPK/SREBP1/ACC/HMGCR Signaling Pathway. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
113	Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC. <i>Frontiers in Oncology</i> , 2021, 11, 783339.	1.3	4

#	ARTICLE	IF	CITATIONS
114	MicroRNA-665-3p exacerbates nonalcoholic fatty liver disease in mice. <i>Bioengineered</i> , 2022, 13, 2927-2942.	1.4	9
115	Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. <i>World Journal of Gastroenterology</i> , 2022, 28, 310-331.	1.4	29
116	Association of lifestyle behaviors with non-alcoholic fatty liver disease and advanced fibrosis detected by transient elastography among Hispanic/Latinos adults in the U.S.. <i>Ethnicity and Health</i> , 2023, 28, 299-312.	1.5	10
117	Metabolic adaptation of lymphocytes in immunity and disease. <i>Immunity</i> , 2022, 55, 14-30.	6.6	91
118	TMEM88 Modulates Lipid Synthesis and Metabolism Cytokine by Regulating Wnt/ β 2-Catenin Signaling Pathway in Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 798735.	1.6	3
119	The effect of hydroxy citric acid supplementation with calorie-restricted diet on metabolic, atherogenic and inflammatory biomarkers in women with non-alcoholic fatty liver disease: a randomized controlled clinical trial. <i>Food and Function</i> , 2022, 13, 5124-5134.	2.1	11
120	Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?. <i>Hepatology</i> , 2022, 75, 740-753.	3.6	26
121	Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 339-355.	0.7	16
122	T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis. <i>Hepatology</i> , 2022, 75, 1038-1049.	3.6	25
123	Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study. <i>Frontiers in Oncology</i> , 2022, 12, 816472.	1.3	7
124	Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 380-387.e3.	2.4	10
125	Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment. <i>Cancers</i> , 2022, 14, 768.	1.7	1
126	Carboranes as unique pharmacophores in antitumor medicinal chemistry. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 400-416.	2.0	48
127	The role of RNA binding proteins in hepatocellular carcinoma. <i>Advanced Drug Delivery Reviews</i> , 2022, 182, 114114.	6.6	9
128	Association between rs738408, rs738409 and rs139051 polymorphisms in PNPLA3 gene and non-alcoholic fatty liver disease. <i>Gene Reports</i> , 2022, 26, 101472.	0.4	2
129	Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis. <i>Journal of Controlled Release</i> , 2022, 343, 175-186.	4.8	37
130	The Role of Liver Zonation in Physiology, Regeneration, and Disease. <i>Seminars in Liver Disease</i> , 2022, 42, 001-016.	1.8	23
131	The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 2022, 13, 812610.	1.5	14

#	ARTICLE	IF	CITATIONS
132	Association of Serum Vitamin C With NAFLD and MAFLD Among Adults in the United States. <i>Frontiers in Nutrition</i> , 2021, 8, 795391.	1.6	13
133	Liver cancer risk-predictive molecular biomarkers specific to clinico-epidemiological contexts. <i>Advances in Cancer Research</i> , 2022, , .	1.9	0
134	Nonalcoholic Fatty Liver Disease in Lean Chinese: The Public Health Crisis We Can No Longer Ignore. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
135	Causes and functional intricacies of inter- and intratumor heterogeneity of primary liver cancers. <i>Advances in Cancer Research</i> , 2022, , .	1.9	0
136	Mechanisms and clinical significance of TGF- β 2 in hepatocellular cancer progression. <i>Advances in Cancer Research</i> , 2022, , 227-248.	1.9	3
138	From MAFLD to hepatocellular carcinoma and everything in between. <i>Chinese Medical Journal</i> , 2022, 135, 547-556.	0.9	19
139	Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2668.	1.8	42
140	β -Catenin signaling in hepatocellular carcinoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	80
141	Comparative efficacy of an optimal exam between ultrasound versus abbreviated <i><sc>MRI</sc></i> for <i><sc>HCC</sc></i> screening in <i><sc>NAFLD</sc></i> cirrhosis: A prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 820-827.	1.9	30
142	The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update. <i>BioScience Trends</i> , 2022, 16, 20-30.	1.1	53
143	The E3 ubiquitin-protein ligase Trim31 alleviates non-alcoholic fatty liver disease by targeting Rhd2 in mouse hepatocytes. <i>Nature Communications</i> , 2022, 13, 1052.	5.8	23
144	Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease. <i>Frontiers in Pharmacology</i> , 2022, 13, 843872.	1.6	5
145	Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 483-496.	4.5	49
146	Editorial: suboptimal ultrasound visualisation in patients undergoing surveillance for hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 752-753.	1.9	2
147	Psoralen Suppresses Lipid Deposition by Alleviating Insulin Resistance and Promoting Autophagy in Oleate-Induced L02 Cells. <i>Cells</i> , 2022, 11, 1067.	1.8	4
148	Editorial Comment: Is Quantitative CT Fat Fraction Ready for Prime Time?. <i>American Journal of Roentgenology</i> , 2021, , 13-13.	1.0	0
149	Review article: current and emerging therapies for the management of cirrhosis and its complications. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1099-1115.	1.9	20
150	Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate-Stage Hepatocellular Carcinoma, What Else Can We Do?. <i>Frontiers in Oncology</i> , 2022, 12, 824799.	1.3	3

#	ARTICLE	IF	CITATIONS
151	Curcuma rhizoma and its major constituents against hepatobiliary disease: Pharmacotherapeutic properties and potential clinical applications. <i>Phytomedicine</i> , 2022, 102, 154090.	2.3	19
152	Unique molecular characteristics of NAFLD-associated liver cancer accentuate β -catenin/TNFRSF19-mediated immune evasion. <i>Journal of Hepatology</i> , 2022, 77, 410-423.	1.8	13
153	Global and regional long-term survival following resection for HCC in the recent decade: A meta-analysis of 110 studies. <i>Hepatology Communications</i> , 2022, 6, 1813-1826.	2.0	29
154	Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2022, 52, 497-507.	1.8	26
156	The Mechanism Underlying the Influence of Indole-3-Propionic Acid: A Relevance to Metabolic Disorders. <i>Frontiers in Endocrinology</i> , 2022, 13, 841703.	1.5	26
157	<i>Porphyromonas gingivalis</i> Induces Increases in Branched-Chain Amino Acid Levels and Exacerbates Liver Injury Through livh/livk. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 776996.	1.8	1
158	Bioinformatics Analysis Combined With Experiments Predicts PUDP as a Potential Prognostic Biomarker for Hepatocellular Carcinoma Through Its Interaction With Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2022, 12, 830174.	1.3	4
159	Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis. <i>Hepatology International</i> , 2022, 16, 269-281.	1.9	23
160	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología y Hepatología</i> , 2022, 45, 724-734.	0.2	3
161	Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 670-680.e18.	2.4	22
162	Risk of intra-abdominal seeding after laparoscopic-assisted thermal ablation of exophytic hepatocellular carcinoma tumors. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 7569-7576.	1.3	2
163	Identification of a Novel Glycosyltransferase Prognostic Signature in Hepatocellular Carcinoma Based on LASSO Algorithm. <i>Frontiers in Genetics</i> , 2022, 13, 823728.	1.1	2
164	Anthraquinone derivatives as ADP-competitive inhibitors of liver pyruvate kinase. <i>European Journal of Medicinal Chemistry</i> , 2022, 234, 114270.	2.6	8
165	Hepatic Glycogenosis: An Underdiagnosed Entity?. <i>Cureus</i> , 2022, 14, e23853.	0.2	0
166	Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. <i>Lancet Oncology</i> , 2022, 23, 521-530.	5.1	116
167	Combined Hepatocellular-Cholangiocarcinoma: What the Multidisciplinary Team Should Know. <i>Diagnostics</i> , 2022, 12, 890.	1.3	17
168	Ethnic and sex differences in hepatic lipid content and related cardiometabolic parameters in lean individuals. <i>JCI Insight</i> , 2022, 7, .	2.3	6
169	Targeting macrophagic 17β -HSD7 by fenretinide for the treatment of nonalcoholic fatty liver disease. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 142-156.	5.7	3

#	ARTICLE	IF	CITATIONS
170	Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. <i>Journal of Hepatology</i> , 2022, 77, 748-760.	1.8	57
171	Epidemiological and Clinical Characteristics of Five Rare Pathological Subtypes of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 864106.	1.3	6
172	TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2022, 76, 910-920.	1.8	27
173	NUSAP1 Could be a Potential Target for Preventing NAFLD Progression to Liver Cancer. <i>Frontiers in Pharmacology</i> , 2022, 13, 823140.	1.6	5
174	Changing epidemiology of hepatocellular carcinoma in Asia. <i>Liver International</i> , 2022, 42, 2029-2041.	1.9	105
175	The present and future of gastroenterology and hepatology: an international SWOT analysis (the Tj ETQq1 1 0.784314 rgBT _g Overload	3.7	
176	Sterol carrier protein 2 in lipid metabolism and non-alcoholic fatty liver disease: Pathophysiology, molecular biology, and potential clinical implications. <i>Metabolism: Clinical and Experimental</i> , 2022, 131, 155180.	1.5	9
177	Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2022, 27, 100699.	0.6	2
178	Lactational High Fat Diet in Mice Causes Insulin Resistance and NAFLD in Male Offspring Which Is Partially Rescued by Maternal Metformin Treatment. <i>Frontiers in Nutrition</i> , 2021, 8, 759690.	1.6	3
179	GDI2 is a novel diagnostic and prognostic biomarker in hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 25304-25324.	1.4	11
180	REXO4 acts as a biomarker and promotes hepatocellular carcinoma progression. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 3093-3106.	0.6	5
181	Mitochondrial Targeting Therapeutics: Promising Role of Natural Products in Non-alcoholic Fatty Liver Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 796207.	1.6	20
182	Association of metabolic health phenotypes, obesity, and hepatocellular carcinoma risk. <i>Digestive and Liver Disease</i> , 2022, 54, 964-972.	0.4	8
183	NAFLD Associated Comorbidity. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2021, , 5-13.	0.1	3
184	Metabolic Reprogramming of Liver Fibrosis. <i>Cells</i> , 2021, 10, 3604.	1.8	16
185	Diet and Gut Microbiota Interaction-Derived Metabolites and Intrahepatic Immune Response in NAFLD Development and Treatment. <i>Biomedicines</i> , 2021, 9, 1893.	1.4	8
187	Hepatocellular Carcinoma and Obesity, Type 2 Diabetes Mellitus, Cardiovascular Disease: Causing Factors, Molecular Links, and Treatment Options. <i>Frontiers in Endocrinology</i> , 2021, 12, 808526.	1.5	24
188	Triglyceride Glucose-Waist Circumference Is Superior to the Homeostasis Model Assessment of Insulin Resistance in Identifying Nonalcoholic Fatty Liver Disease in Healthy Subjects. <i>Journal of Clinical Medicine</i> , 2022, 11, 41.	1.0	12

#	ARTICLE	IF	CITATIONS
189	Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities. <i>Frontiers in Endocrinology</i> , 2021, 12, 777075.	1.5	8
190	Involvement of STING signaling pathway in non-alcoholic fatty liver disease. <i>World Chinese Journal of Digestology</i> , 2021, 29, 1396-1401.	0.0	1
191	Sarcopenia in Hepatocellular Carcinoma: Pathogenesis and Management. <i>Chemotherapy</i> , 2022, 67, 152-163.	0.8	10
192	MicroRNA-137-3p Improves Nonalcoholic Fatty Liver Disease through Activating AMPK $\hat{\pm}$. <i>Analytical Cellular Pathology</i> , 2021, 2021, 1-13.	0.7	3
193	Positive association of nap duration with risk of non-alcoholic fatty liver disease in an occupational population in Guangdong Province, China: a cross-sectional study. <i>BMC Gastroenterology</i> , 2022, 22, 185.	0.8	1
194	Prophylactic role of <i>Premna herbacea</i> , a dietary leafy vegetable in managing hepatic steatosis via regulating AMPK/SREBP1/ACC/HMGCR signaling pathway. <i>Food Bioscience</i> , 2022, 48, 101720.	2.0	3
195	Hmgcs2-mediated ketogenesis modulates high-fat diet-induced hepatosteatosis. <i>Molecular Metabolism</i> , 2022, 61, 101494.	3.0	28
196	Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria. <i>Frontiers in Medicine</i> , 2022, 9, 869190.	1.2	8
197	Editorial: screening for hepatocellular carcinoma in <sc>NAFLD</sc>â€”towards abbreviated <sc>MRI</sc> alternative in patients with obesity?. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1210-1211.	1.9	2
198	Editorial: screening for hepatocellular carcinoma in <sc>NAFLD</sc> cirrhosisâ€”towards abbreviated <sc>MRI</sc> alternative in patients with obesity? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1212-1213.	1.9	0
199	Influence of Metabolic Risk Factors on the Risk of Bacterial Infections in Hepatitis B-Related Cirrhosis: A 10-Year Cohort Study. <i>Frontiers in Medicine</i> , 2022, 9, 847091.	1.2	0
200	Intestinal peroxisome proliferatorâ€”activated receptor $\hat{\pm}$ â€”fatty acidâ€”binding protein 1 axis modulates nonalcoholic steatohepatitis. <i>Hepatology</i> , 2023, 77, 239-255.	3.6	36
201	Decreased ARG1 expression as an adverse prognostic phenotype in non-alcoholic non-virus-related hepatocellular carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 253-263.	1.4	1
203	Macrophages as key regulators of liver health and disease. <i>International Review of Cell and Molecular Biology</i> , 2022, , 143-212.	1.6	18
204	Prognosis after Hepatic Resection of Patients with Hepatocellular Carcinoma Related to NAFLD or MAFLD: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
206	NAFLDâ€”related hepatocellular carcinoma: The growing challenge. <i>Hepatology</i> , 2023, 77, 323-338.	3.6	62
207	The functional role of Higd1a in mitochondrial homeostasis and in multiple disease processes. <i>Genes and Diseases</i> , 2023, 10, 1833-1845.	1.5	7
208	Application and progress of the detection technologies in hepatocellular carcinoma. <i>Genes and Diseases</i> , 2023, 10, 1857-1869.	1.5	6

#	ARTICLE	IF	CITATIONS
209	Livogrit Prevents Methionine-Cystine Deficiency Induced Nonalcoholic Steatohepatitis by Modulation of Steatosis and Oxidative Stress in Human Hepatocyte-Derived Spheroid and in Primary Rat Hepatocytes. <i>Bioengineered</i> , 2022, 13, 10811-10826.	1.4	7
210	Acacetin Protects against Non-Alcoholic Fatty Liver Disease by Regulating Lipid Accumulation and Inflammation in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4687.	1.8	12
211	Does Metabolic Syndrome Effect the Perioperative Course and Costs of Patients With Hepatocellular Carcinoma Undergoing Robotic Hepatectomy? A Propensity Score-Matched Analysis. <i>American Surgeon</i> , 2022, 88, 2108-2114.	0.4	2
212	The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	1
213	RGS7-ATF3-Tip60 Complex Promotes Hepatic Steatosis and Fibrosis by Directly Inducing TNF α . <i>Antioxidants and Redox Signaling</i> , 2023, 38, 137-159.	2.5	4
214	Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 931-939.e5.	2.4	42
215	A minority of somatically mutated genes in pre-existing fatty liver disease have prognostic importance in the development of <sc>NAFLD</sc>. <i>Liver International</i> , 2022, 42, 1823-1835.	1.9	3
216	A Prognosis Marker Dynein Cytoplasmic 1 Heavy Chain 1 Correlates with EMT and Immune Signature in Liver Hepatocellular Carcinoma by Bioinformatics and Experimental Analysis. <i>Disease Markers</i> , 2022, 2022, 1-18.	0.6	7
217	Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis. <i>Digestive and Liver Disease</i> , 2022, 54, 1392-1402.	0.4	7
218	Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 790-801.	4.5	40
219	Genomic and transcriptomic somatic alterations of hepatocellular carcinoma in non-cirrhotic livers. <i>Cancer Genetics</i> , 2022, 264-265, 90-99.	0.2	3
220	Liver cirrhosis: An overview of experimental models in rodents. <i>Life Sciences</i> , 2022, 301, 120615.	2.0	18
221	Croatian guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease. <i>Acta Clinica Croatica</i> , 2021, 60, 36-52.	0.1	0
222	Risk factors for non-alcoholic fatty liver disease delineate the battlegrounds in optimizing disease prevention. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, .	0.7	0
223	Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2022, 13, 96-106.	0.5	6
224	Modulation of Oxidative Stress-Induced Senescence during Non-Alcoholic Fatty Liver Disease. <i>Antioxidants</i> , 2022, 11, 975.	2.2	3
225	Macrophages evoke autophagy of hepatic stellate cells to promote liver fibrosis in NAFLD mice via the PGE2/EP4 pathway. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 303.	2.4	20
227	Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 955-964.	0.7	9

#	ARTICLE	IF	CITATIONS
228	Association Between Monocyte to High-Density Lipoprotein Cholesterol Ratio and Risk of Non-alcoholic Fatty Liver Disease: A Cross-Sectional Study. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	10
229	Identification of Epsin1 as a regulator for hepatic lipid and glucose metabolism. <i>Genes and Diseases</i> , 2023, 10, 72-75.	1.5	0
230	The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review. <i>Cureus</i> , 2022, , .	0.2	3
231	Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver. , 2022, 19, 834-847.		33
232	Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 559-568.	0.6	13
233	The Regulatory Roles of Polysaccharides and Ferroptosis-Related Phytochemicals in Liver Diseases. <i>Nutrients</i> , 2022, 14, 2303.	1.7	13
234	Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. <i>Cell Metabolism</i> , 2022, 34, 969-977.e2.	7.2	163
235	Clinical features and outcomes of NAFLD-related hepatocellular carcinoma – Authors' reply. <i>Lancet Oncology</i> , The, 2022, 23, e244.	5.1	1
236	Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial. <i>Trials</i> , 2022, 23, .	0.7	0
237	Exosomes From Cancer-Associated Mesenchymal Stem Cells Transmit TMBIM6 to Promote the Malignant Behavior of Hepatocellular Carcinoma via Activating PI3K/AKT Pathway. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
238	Sphingosine kinase 1 mediates sexual dimorphism in fibrosis in a mouse model of NASH. <i>Molecular Metabolism</i> , 2022, 62, 101523.	3.0	5
239	Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids. <i>Seminars in Liver Disease</i> , 2022, 42, 122-137.	1.8	3
240	The effect of a fruit-rich diet on liver biomarkers, insulin resistance, and lipid profile in patients with non-alcoholic fatty liver disease: a randomized clinical trial. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 1238-1249.	0.6	10
242	Preoperative PDW levels predict pulmonary metastasis in patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
243	<scp>LPS</scp>-induced macrophage exosomes promote the activation of hepatic stellate cells and the intervention study of total astragalus saponins combined with glycyrrhizic acid. <i>Anatomical Record</i> , 2023, 306, 3097-3105.	0.8	4
244	Identification of Key Biomarkers and Immune Infiltration in Liver Tissue after Bariatric Surgery. <i>Disease Markers</i> , 2022, 2022, 1-17.	0.6	4
245	Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease. <i>Genome Medicine</i> , 2022, 14, .	3.6	12
246	Microarray analysis of mRNA expression profiles in liver of ob/ob mice with real-time atmospheric PM2.5 exposure. <i>Environmental Science and Pollution Research</i> , 2022, 29, 76816-76832.	2.7	1

#	ARTICLE	IF	CITATIONS
247	Knockdown of TANK-Binding Kinase 1 Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular-Targeted Drugs. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
248	Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report. <i>Current Oncology</i> , 2022, 29, 4267-4273.	0.9	18
249	Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits. <i>Journal of Hepatology</i> , 2022, 77, 1136-1160.	1.8	136
250	The potential role of FNDC5/irisin in various liver diseases: awakening the sleeping beauties. <i>Expert Reviews in Molecular Medicine</i> , 0, , 1-42.	1.6	3
251	A Single Nucleotide Mixture Enhances the Antitumor Activity of Molecular-Targeted Drugs Against Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
252	Effect of Exercise Training on Serum Transaminases in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	5
253	Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7280.	1.8	38
254	Emerging insights on immunotherapy in liver cancer. <i>Antioxidants and Redox Signaling</i> , 0, , .	2.5	4
255	Baicalein Prevents Fructose-Induced Hepatic Steatosis in Rats: In the Regulation of Fatty Acid De Novo Synthesis, Fatty Acid Elongation and Fatty Acid Oxidation. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
256	KHK, PNPLA3 and PPAR as Novel Targets for the Anti-Steatotic Action of Bempedoic Acid. <i>Biomedicines</i> , 2022, 10, 1517.	1.4	6
257	The Absence of STING Ameliorates Non-Alcoholic Fatty Liver Disease and Reforms Gut Bacterial Community. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
258	Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC). <i>Digestive Diseases and Sciences</i> , 0, , .	1.1	2
259	Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 939-946.	0.7	24
260	Risk of various cancers in adults with abdominal aortic aneurysms. <i>Journal of Vascular Surgery</i> , 2023, 77, 80-88.e2.	0.6	1
261	Progress and Prospects of Non-Canonical NF- κ B Signaling Pathway in the Regulation of Liver Diseases. <i>Molecules</i> , 2022, 27, 4275.	1.7	3
262	Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives. <i>World Journal of Gastroenterology</i> , 2022, 28, 3410-3421.	1.4	7
263	Diagnostic Performance of Attenuation to Stage Liver Steatosis with MRI Proton Density Fat Fraction as Reference: A Prospective Comparison of Three US Machines. <i>Radiology</i> , 2022, 305, 353-361.	3.6	7
264	Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular Carcinoma. <i>Journal of Immunology Research</i> , 2022, 2022, 1-10.	0.9	1

#	ARTICLE	IF	CITATIONS
265	Exploring Anti-Nonalcoholic Fatty Liver Disease Mechanism of Gardeniae Fructus by Network Pharmacology, Molecular Docking, and Experiment Validation. <i>ACS Omega</i> , 2022, 7, 25521-25531.	1.6	7
266	Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 1036-1048.	3.7	9
267	Letter to the Editor: Several issues to consider in the study of hepatocellular carcinoma progression mechanism. <i>Hepatology</i> , 2023, 78, E1-E2.	3.6	0
268	Diagnostic scores and scales for appraising Nonalcoholic fatty liver disease and omics perspectives for precision medicine. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2022, 25, 285-291.	1.3	5
269	Non-alcoholic Fatty Liver Disease and Depression: Evidence for Genotype × Environment Interaction in Mexican Americans. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	3
270	Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 1553-1584.	1.2	6
271	Emerging Role of Hepatic Ketogenesis in Fatty Liver Disease. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	32
272	Bile acids and sphingolipids in non-alcoholic fatty liver disease. <i>Chinese Medical Journal</i> , 2022, 135, 1163-1171.	0.9	8
273	Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	6
274	New horizon of ultrasound for screening and surveillance of non-alcoholic fatty liver disease spectrum. <i>European Journal of Radiology</i> , 2022, 154, 110450.	1.2	1
275	The impact of non-alcoholic fatty liver disease on sleep apnea in healthy adults: A nationwide study of Korea. <i>PLoS ONE</i> , 2022, 17, e0271021.	1.1	3
276	Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	14
277	Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1750-1760.e12.	2.4	43
278	Characteristics and outcomes of hepatocellular carcinoma patients with macrovascular invasion following surgical resection: a meta-analysis of 40 studies and 8,218 patients. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 848-860.	0.7	4
279	COVID-19 Pandemic: Insights into Interactions between SARS-CoV-2 Infection and MAFLD. <i>International Journal of Biological Sciences</i> , 2022, 18, 4756-4767.	2.6	5
280	A maternal high-fat diet induces fetal origins of NASH-HCC in mice. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
281	HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma. <i>Hepatology</i> , 2023, 77, 774-788.	3.6	24
282	Effect of Ayurveda interventions in non-alcoholic grade II fatty liver associated with obesity – A case report. <i>Journal of Ayurveda and Integrative Medicine</i> , 2022, 13, 100605.	0.9	2

#	ARTICLE	IF	CITATIONS
283	Gut microbiota contribution to hepatocellular carcinoma manifestation in non-alcoholic steatohepatitis. <i>World Journal of Hepatology</i> , 2022, 14, 1277-1290.	0.8	1
284	Luteolin alleviates methionineâ€“choline-deficient diet-induced non-alcoholic steatohepatitis by modulating host serum metabolome and gut microbiome. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	7
285	Much more is needed from Hepatitis B Core-related antigen to predict Risk of Liver cancer. <i>American Journal of Gastroenterology</i> , 2022, Publish Ahead of Print, .	0.2	1
286	Targeted Proteomics for Monitoring One-Carbon Metabolism in Liver Diseases. <i>Metabolites</i> , 2022, 12, 779.	1.3	4
287	Acylâ€“CoA thioesterase 9 promotes tumour growth and metastasis through reprogramming of fatty acid metabolism in hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 2548-2561.	1.9	2
288	Usefulness of the SAF score to characterize NAFLD/NASH in non-cirrhotic HCV patients. <i>Egyptian Liver Journal</i> , 2022, 12, .	0.3	0
289	Advances of cancer-associated fibroblasts in liver cancer. <i>Biomarker Research</i> , 2022, 10, .	2.8	21
290	Association Between NLR and NAFLD in Adults Exposed to Famine in Early Life. <i>Risk Management and Healthcare Policy</i> , 0, Volume 15, 1561-1568.	1.2	0
291	Obesity Management in the Primary Prevention of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 4051.	1.7	11
292	Primary-like Human Hepatocytes Genetically Engineered to Obtain Proliferation Competence as a Capable Application for Energy Metabolism Experiments in In Vitro Oncologic Liver Models. <i>Biology</i> , 2022, 11, 1195.	1.3	2
293	The association between non-alcoholic fatty liver disease (NAFLD) and advanced fibrosis with blood selenium level based on the NHANES 2017-2018. <i>Annals of Medicine</i> , 2022, 54, 2258-2267.	1.5	9
294	A cohesinâ€“associated gene score may predict immune checkpoint blockade in hepatocellular carcinoma. <i>FEBS Open Bio</i> , 0, , .	1.0	0
295	Global burden of nonalcoholic steatohepatitis-related liver cancer, 1990â€“2019: a systematic analysis for the GBD 2019. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	1.2	7
296	Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD. <i>Seminars in Liver Disease</i> , 2022, 42, 233-249.	1.8	8
297	Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 120-134.	4.5	20
298	Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. <i>Journal of Hepatology</i> , 2022, 77, 1482-1490.	1.8	37
299	Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	90
300	Gender Differences in Nonalcoholic Fatty Liver Disease. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2022, 12, S19-S25.	0.1	5

#	ARTICLE	IF	CITATIONS
301	The role of dietary factors in nonalcoholic fatty liver disease to hepatocellular carcinoma progression: A systematic review. <i>Clinical Nutrition</i> , 2022, 41, 2295-2307.	2.3	12
302	Shared Mechanisms between Cardiovascular Disease and NAFLD. <i>Seminars in Liver Disease</i> , 2022, 42, 455-464.	1.8	11
303	Interplay between fatty acids, SCD, mTORC1 and YAP/TAZ in promoting hepatocellular carcinoma. , 2022, , .		1
306	MicroRNA-379-5p regulates free cholesterol accumulation and relieves diet induced-liver damage in db/db mice via STAT1/HMGCS1 axis. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	5
307	Advances in novel systemic therapies for advanced hepatocellular carcinoma. <i>Future Medicinal Chemistry</i> , 0, , .	1.1	1
308	mTOR: A Potential New Target in Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9196.	1.8	21
309	Long non-coding RNA SNHG6 couples cholesterol sensing with mTORC1 activation in hepatocellular carcinoma. <i>Nature Metabolism</i> , 2022, 4, 1022-1040.	5.1	29
310	Combined exposure to PM2.5 and high-fat diet facilitates the hepatic lipid metabolism disorders via ROS/miR-155/PPAR β pathway. <i>Free Radical Biology and Medicine</i> , 2022, 190, 16-27.	1.3	6
311	Analysis of environmental chemical mixtures and nonalcoholic fatty liver disease: NHANES 1999â€“2014. <i>Environmental Pollution</i> , 2022, 311, 119915.	3.7	20
312	CX3CL1/CX3CR1 interaction protects against lipotoxicity-induced nonalcoholic steatohepatitis by regulating macrophage migration and M1/M2 status. <i>Metabolism: Clinical and Experimental</i> , 2022, 136, 155272.	1.5	20
313	Imipramine activates FAM3A-FOXA2-CPT2 pathway to ameliorate hepatic steatosis. <i>Metabolism: Clinical and Experimental</i> , 2022, 136, 155292.	1.5	5
314	Role of the Ghrelin System in Colitis and Hepatitis as Risk Factors for Inflammatory-Related Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11188.	1.8	0
315	Is ageing a problematic hurdle to the efficacy of firstâ€“line atezolizumab plus bevacizumab in hepatocellular carcinoma?. <i>Liver International</i> , 2022, 42, 2352-2353.	1.9	0
316	Risk stratification and early detection biomarkers for precision HCC screening. <i>Hepatology</i> , 2023, 78, 319-362.	3.6	13
317	Hepatic gene expression and functional changes associated with nonalcoholic steatohepatitis. <i>Molecular Medicine Reports</i> , 2022, 26, .	1.1	1
318	Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective. <i>Pharmacological Research</i> , 2022, 184, 106426.	3.1	6
319	Effects of targeted-edited oncogenic insulin-like growth factor-1 receptor with specific-sgRNA on biological behaviors of HepG2 cells. <i>World Journal of Clinical Cases</i> , 0, 10, 10017-10030.	0.3	0
320	Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms. <i>Life Sciences</i> , 2022, 308, 120956.	2.0	14

#	ARTICLE	IF	CITATIONS
321	Combined genetic deletion of GDF15 and FGF21 has modest effects on body weight, hepatic steatosis and insulin resistance in high fat fed mice. <i>Molecular Metabolism</i> , 2022, 65, 101589.	3.0	10
322	Neurotrophic factors stimulate the activation of hepatic stellate cells in liver fibrosis. <i>Biochemical and Biophysical Research Communications</i> , 2022, 630, 167-174.	1.0	3
323	The growing threat of non-alcoholic fatty liver disease-related hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 735-737.	0.7	1
324	Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model. <i>Gastroenterology Report</i> , 2022, 10, .	0.6	4
325	Chemoprevention of Hepatocellular Carcinoma with Statins, Aspirin and Metformin: Systematic Review and Meta-Analysis of Matched Studies. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
326	ALKBH5/MAP3K8 axis regulates PD-L1+ macrophage infiltration and promotes hepatocellular carcinoma progression. <i>International Journal of Biological Sciences</i> , 2022, 18, 5001-5018.	2.6	33
327	The contribution of the gut-liver axis to the immune signaling pathway of NAFLD. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
329	Neutrophilâ€lymphocyte ratio in relation to risk of hepatocellular carcinoma in patients with nonâ€alcoholic fatty liver disease. <i>Cancer Medicine</i> , 2023, 12, 3589-3600.	1.3	5
330	Clinical and Metabolic Characteristics of Hyperuricemia with Risk of Liver Fibrosis: A Cross-Sectional Study. <i>Metabolites</i> , 2022, 12, 893.	1.3	1
331	Association of Metabolic Signatures with Nonalcoholic Fatty Liver Disease in Pediatric Population. <i>Metabolites</i> , 2022, 12, 881.	1.3	3
332	Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH. <i>Hepatology</i> , 2023, 77, 1150-1163.	3.6	41
333	Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	2
334	Treatment Strategies and Mechanisms Associated with the Prevention of NASH-Associated HCC by a Toll-like Receptor 4 Inhibitor. <i>Cancer Prevention Research</i> , 2023, 16, 17-28.	0.7	1
335	Advances in metformin for the treatment of non-alcoholic fatty liver disease in children. <i>Expert Review of Gastroenterology and Hepatology</i> , 0, , 1-15.	1.4	1
336	S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11030.	1.8	5
337	Geographical similarity and differences in the burden and genetic predisposition of NAFLD. <i>Hepatology</i> , 2023, 77, 1404-1427.	3.6	43
338	CT Characteristics of Acute Pancreatitis with Preexisting Fatty Liver and Its Impact on Pancreatitis Severity and Persistent Systemic Inflammatory Response Syndrome. <i>International Journal of General Medicine</i> , 0, Volume 15, 7017-7028.	0.8	0
339	Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis. <i>PLoS ONE</i> , 2022, 17, e0274519.	1.1	18

#	ARTICLE	IF	CITATIONS
340	All Roads Lead to Cathepsins: The Role of Cathepsins in Non-Alcoholic Steatohepatitis-Induced Hepatocellular Carcinoma. <i>Biomedicines</i> , 2022, 10, 2351.	1.4	1
341	Andrographolide ameliorates hepatic steatosis by suppressing FATP2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease. <i>Journal of Natural Medicines</i> , 2023, 77, 73-86.	1.1	6
342	Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	19
344	Hepatocyte-targeting and tumor microenvironment-responsive liposomes for enhanced anti-hepatocarcinoma efficacy. <i>Drug Delivery</i> , 2022, 29, 2995-3008.	2.5	2
345	Liver steatosis and fibrosis markers' association with cardiovascular and renal damage in Japanese adults: the TMM BirThree cohort study. <i>Annals of Hepatology</i> , 2022, , 100761.	0.6	2
346	Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 77, 1642-1656.	1.8	13
347	Accuracy of Ultrasound Elastography and Fibrosis-4 Index (FIB-4) in Ruling Out Cirrhosis in Obese Non-Alcoholic Fatty Liver Disease (NAFLD) Patients. <i>Cureus</i> , 2022, , .	0.2	0
348	NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy. <i>Clinical Cancer Research</i> , 2023, 29, 513-520.	3.2	30
349	Gut microbiome and microbial metabolites in NAFLD and after bariatric surgery: Correlation and causality. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	16
350	Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
351	Evaluation of Six Noninvasive Methods for the Detection of Fibrosis in Chinese Patients with Obesity and Nonalcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 0, , .	1.1	0
352	Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. <i>Gut</i> , 2023, 72, 581-589.	6.1	21
353	HCV and tumor-initiating stem-like cells. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	1
354	Factors associated with the development of extrahepatic malignancy in patients with nonalcoholic fatty liver disease: a single-center longitudinal study. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 1172-1177.	0.8	0
355	Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis. <i>Hepatology</i> , 2023, 77, 1735-1745.	3.6	24
356	Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 1622-1636.	0.8	6
357	Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma. <i>Molecular Therapy</i> , 2023, 31, 119-133.	3.7	13
358	Zinc fingers and homeoboxes 2 is required for diethylnitrosamine-induced liver tumor formation in C57BL/6 mice. <i>Hepatology Communications</i> , 2022, 6, 3550-3562.	2.0	5

#	ARTICLE	IF	CITATIONS
359	Integrated Bioinformatics and Experimental Analysis Identified TRIM28 a Potential Prognostic Biomarker and Correlated with Immune Infiltrates in Liver Hepatocellular Carcinoma. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-17.	0.7	3
360	Unrecognized liver cirrhosis is common and associated with worse survival in hepatocellular carcinoma: A nationwide cohort study of 3473 patients. <i>Journal of Internal Medicine</i> , 2023, 293, 184-199.	2.7	3
361	Incidence and Predictors of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 37-47.	0.4	3
362	The risk of hepatocellular carcinoma of the liver in non-alcoholic fatty liver disease: features of prevention and treatment. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2022, , 284-289.	0.1	0
363	Dihydroflavonoid glycosides from <i>Viscum album</i> and their inhibitory effects on hepatic lipid accumulation and target identification. <i>Phytochemistry</i> , 2022, 204, 113458.	1.4	1
364	Hippocalcin-Like 1 blunts liver lipid metabolism to suppress tumorigenesis via directly targeting RUVBL1-mTOR signaling. <i>Theranostics</i> , 2022, 12, 7450-7464.	4.6	5
365	A Review of Research Trends in Traditional Korean Medicine for Nonalcoholic Fatty Liver Disease. <i>The Journal of Internal Korean Medicine</i> , 2022, 43, 680-719.	0.0	0
366	The Emerging Role of Extracellular Vesicles and Autophagy Machinery in NASH—Future Horizons in NASH Management. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12185.	1.8	6
367	Blood and urine manganese exposure in non-alcoholic fatty liver disease and advanced liver fibrosis: an observational study. <i>Environmental Science and Pollution Research</i> , 2023, 30, 22222-22231.	2.7	4
368	Synergistic activation of AMPK by AdipoR1/2 agonist and inhibitor of EDPs—EBP interaction recover NAFLD through enhancing mitochondrial function in mice. <i>Acta Pharmaceutica Sinica B</i> , 2022, , .	5.7	3
369	The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12370.	1.8	7
371	Renofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single-blind, placebo-controlled study in F2/F3 NASH. <i>Hepatology Communications</i> , 2022, 6, 3379-3392.	2.0	9
372	Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras. <i>Clinical Infectious Diseases</i> , 2023, 76, 592-599.	2.9	2
373	Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancers. <i>Hepatology Communications</i> , 2022, 6, 3299-3310.	2.0	6
374	The STING in Non-Alcoholic Fatty Liver Diseases: Potential Therapeutic Targets in Inflammation-Carcinogenesis Pathway. <i>Pharmaceutics</i> , 2022, 15, 1241.	1.7	2
375	Deciphering the role of aberrant DNA methylation in NAFLD and NASH. <i>Heliyon</i> , 2022, 8, e11119.	1.4	8
376	A Novel Cuproptosis-Related Signature Identified DLAT as a Prognostic Biomarker for Hepatocellular Carcinoma Patients. <i>World Journal of Oncology</i> , 2022, 13, 299-310.	0.6	14
377	Hepatic glutamine synthetase controls N5-methylglutamine in homeostasis and cancer. <i>Nature Chemical Biology</i> , 2023, 19, 292-300.	3.9	7

#	ARTICLE	IF	CITATIONS
378	RNA binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expression. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	4
379	Local ablation of hepatocellular carcinoma by interstitial brachytherapy: prediction of outcome by diffusion-weighted imaging. <i>Acta Radiologica</i> , 2023, 64, 1331-1340.	0.5	1
380	Male zooid extracts of <i>Antheraea pernyi</i> ameliorates non-alcoholic fatty liver disease and intestinal dysbacteriosis in mice induced by a high-fat diet. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	0
381	Novel therapeutic targets in liver pathology: From basic science to clinical translation. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 1529-1531.	1.2	0
382	Impact of metabolic syndrome on the long-term prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after hepatectomy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
383	Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2023, 43, 089-099.	1.8	2
384	Magnesium Supplementation Stimulates Autophagy to Reduce Lipid Accumulation in Hepatocytes via the AMPK/mTOR Pathway. <i>Biological Trace Element Research</i> , 2023, 201, 3311-3322.	1.9	4
385	Lipid droplet turnover at the lysosome inhibits growth of hepatocellular carcinoma in a BNIP3-dependent manner. <i>Science Advances</i> , 2022, 8, .	4.7	15
386	Potential hepatoprotective effects of <i>Cistanche deserticola</i> Y.C. Ma: Integrated phytochemical analysis using UPLC-Q-TOF-MS/MS, target network analysis, and experimental assessment. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
387	Relationship between liver fat content and lifestyle factors in adults with metabolic syndrome. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
388	Treating inflammation to combat non-alcoholic fatty liver disease. <i>Journal of Endocrinology</i> , 2023, 256, .	1.2	21
389	<i>Lactobacillus sakei</i> MJM60958 as a Potential Probiotic Alleviated Non-Alcoholic Fatty Liver Disease in Mice Fed a High-Fat Diet by Modulating Lipid Metabolism, Inflammation, and Gut Microbiota. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13436.	1.8	15
390	Recreational Drugs and the Risk of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 5395.	1.7	3
391	Discussing the role of circular RNA in the pathogenesis of non-alcoholic fatty liver disease and its complications. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
392	TGF- β 1 contributes to the hepatic inflammation in animal models with nonalcoholic steatohepatitis by Smad3/TLR2 signaling pathway. <i>Molecular Immunology</i> , 2022, 152, 129-139.	1.0	2
393	Accurate determination for lipidomics based on LC-tandem-MS parameters modeling, prediction, and database: Monitoring the progression of hepatocellular carcinoma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2023, 223, 115126.	1.4	1
394	Antidiabetic drug metformin suppresses tumorigenesis through inhibition of mevalonate pathway enzyme HMGCS1. <i>Journal of Biological Chemistry</i> , 2022, 298, 102678.	1.6	4
395	Gut-“Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome. <i>Biology</i> , 2022, 11, 1622.	1.3	16

#	ARTICLE	IF	CITATIONS
396	Single-cell RNA sequencing reveals a novel inhibitory effect of ApoA4 on NAFL mediated by liver-specific subsets of myeloid cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
397	Evolving therapeutic landscape of advanced hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 203-222.	8.2	113
398	Identification of biomarkers in nonalcoholic fatty liver disease: A machine learning method and experimental study. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
399	Systems biology approach reveals a common molecular basis for COVID-19 and non-alcoholic fatty liver disease (NAFLD). <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	3
400	The regulation and functions of <scp>ACSL3</scp> and <scp>ACSL4</scp> in the liver and hepatocellular carcinoma. <i>Liver Cancer International</i> , 2023, 4, 28-41.	0.2	1
401	Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. <i>Nutrients</i> , 2022, 14, 4673.	1.7	23
402	Plasma phospholipid arachidonic acid in relation to non-alcoholic fatty liver disease: Mendelian randomization study. <i>Nutrition</i> , 2023, 106, 111910.	1.1	5
403	Review article: the role of <scp>HSD17B13</scp> on global epidemiology, natural history, pathogenesis and treatment of <scp>NAFLD</scp>. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 37-51.	1.9	17
404	Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	8
405	Bile Acids: A Bridge Linking Gut Microbiota and NAFLD. , 2022, 2022, 1-14.		2
406	Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2023, 78, 493-500.	1.8	20
407	Fagopyrum dibotrys extract alleviates hepatic steatosis and insulin resistance, and alters autophagy and gut microbiota diversity in mouse models of high-fat diet-induced non-alcoholic fatty liver disease. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	1
408	The Role of Intermittent Fasting in the Management of Nonalcoholic Fatty Liver Disease: A Narrative Review. <i>Nutrients</i> , 2022, 14, 4655.	1.7	11
409	Crucial role of T cells in NAFLD-related disease: A review and prospect. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	4
410	Oncogenic Wnt3a is a promising sensitive biomarker for monitoring hepatocarcinogenesis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, , .	0.6	0
411	DNA methylation status of the SPHK1 and LTB genes underlies the clinicopathological diversity of non-alcoholic steatohepatitis-related hepatocellular carcinomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5109-5125.	1.2	2
412	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. <i>Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). Gastroenterología Y Hepatología (English Edition)</i> , 2022, 45, 724-734.	0.0	0
414	Regulators of Genetic Risk for the Progression of Non-alcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Reconstruction of Transcriptional Network and Signature-Based Metabolic Profiling. , 2022, , 193-227.		0

#	ARTICLE	IF	CITATIONS
415	Protective effect and mechanism of lactoferrin combined with hypoxia against high-fat diet induced obesity and non-alcoholic fatty liver disease in mice. <i>International Journal of Biological Macromolecules</i> , 2023, 227, 839-850.	3.6	5
416	Emerging role of aging in the progression of NAFLD to HCC. <i>Ageing Research Reviews</i> , 2023, 84, 101833.	5.0	21
417	The Role of Senescence in NASH-Related HCC. , 2022, , 167-191.		1
418	Imbalance in ALR ubiquitination accelerates the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma. <i>Oncogene</i> , 2023, 42, 308-321.	2.6	1
419	Aqueous extract of <i>Artemisia capillaris</i> improves non-alcoholic fatty liver and obesity in mice induced by high-fat diet. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
420	PVRâ€™A Prognostic Biomarker Correlated with Immune Cell Infiltration in Hepatocellular Carcinoma. <i>Diagnostics</i> , 2022, 12, 2953.	1.3	1
421	Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1151-1167.	1.9	3
422	Diagnostic performance of novel inflammatory biomarkers based on ratios of laboratory indicators for nonalcoholic fatty liver disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9
423	Shuangyu Tiaozhi decoction alleviates non-alcoholic fatty liver disease by improving lipid deposition, insulin resistance, and inflammation in vitro and in vivo. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
424	Novel Insights into MEG3/miR664a-3p/ADH4 Axis and Its Possible Role in Hepatocellular Carcinoma from an in Silico Perspective. <i>Genes</i> , 2022, 13, 2254.	1.0	2
425	Highlighting novel targets in immunotherapy for liver cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 1029-1041.	1.4	3
426	Non-alcoholic fatty liver disease establishment and progression: genetics and epigenetics as relevant modulators of the pathology. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 521-533.	0.6	0
427	Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2023, 17, 24-33.	1.4	4
428	Mechanistic insights into the pleiotropic effects of butyrate as a potential therapeutic agent on NAFLD management: A systematic review. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	11
429	Liver-derived metabolites as signaling molecules in fatty liver disease. <i>Cellular and Molecular Life Sciences</i> , 2023, 80, .	2.4	8
430	Efficacy and safety of acetyl-CoA carboxylase (ACC) inhibitors in the treatment of nonalcoholic steatohepatitis (NASH): A protocol for systematic review. <i>Medicine (United States)</i> , 2022, 101, e32357.	0.4	0
431	Bariatric Surgery Associates with Nonalcoholic Steatohepatitis/Hepatocellular Carcinoma Amelioration via SPP1 Suppression. <i>Metabolites</i> , 2023, 13, 11.	1.3	0
432	A researcherâ€™s guide to preclinical mouse NASH models. <i>Nature Metabolism</i> , 2022, 4, 1632-1649.	5.1	39

#	ARTICLE	IF	CITATIONS
433	Circulating Metabolic Markers Related to the Diagnosis of Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	1
434	Association between severe hepatic steatosis examined by Fibroscan and the risk of high-risk colorectal neoplasia. <i>PLoS ONE</i> , 2022, 17, e0279242.	1.1	2
435	ASRGL1 downregulation suppresses hepatocellular carcinoma tumorigenesis in a CDK1-dependent manner. <i>Digestive and Liver Disease</i> , 2022, , .	0.4	0
436	The role of bile acid metabolism in the occurrence and development of NAFLD. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	7
437	Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1263-1278.	1.8	2
438	Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies. <i>Cancers</i> , 2023, 15, 23.	1.7	21
439	Weighted Gene Co-Expression Network Analysis of Immune Infiltration in Nonalcoholic Fatty Liver Disease. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 23, .	0.6	1
440	Transient expression of factor VIII and a chronic high-fat diet induces ER stress and late hepatocyte oncogenesis. <i>Molecular Therapy</i> , 2022, 30, 3510-3512.	3.7	1
441	Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 273-302.	0.4	16
442	Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: A systematic analysis of the global burden of disease study 2019. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	12
443	Parthenolide induces rapid thiol oxidation that leads to ferroptosis in hepatocellular carcinoma cells. <i>Frontiers in Toxicology</i> , 0, 4, .	1.6	5
444	Sweeping “Metabolic Dysfunction” off the Front Foot “ Deceived by the “Wrong” Implications of Dysmetabolism Analysis in Healthy Subjects. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 547-548.	0.4	1
445	NAFLD and HBV interplay - related mechanisms underlying liver disease progression. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
446	Histone methylation in pre-cancerous liver diseases and hepatocellular carcinoma: recent overview. <i>Clinical and Translational Oncology</i> , 2023, 25, 1594-1605.	1.2	3
447	Effect of exercise-based interventions in nonalcoholic fatty liver disease: A systematic review with meta-analysis. <i>Digestive and Liver Disease</i> , 2023, 55, 1178-1186.	0.4	5
448	Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 433-452.	4.5	14
449	Dysmetabolic Iron Overload Syndrome: Going beyond the Traditional Risk Factors Associated with Metabolic Syndrome. <i>Endocrines</i> , 2023, 4, 18-37.	0.4	1
450	Programmed cell death and lipid metabolism of macrophages in NAFLD. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6

#	ARTICLE	IF	CITATIONS
451	Role of Hepatic Aryl Hydrocarbon Receptor in Non-Alcoholic Fatty Liver Disease. , 2023, 2, 1-15.		2
452	Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy. Journal of Viral Hepatitis, 0, , .	1.0	1
453	Two-dimensional Convolutional Neural Network Using Quantitative US for Noninvasive Assessment of Hepatic Steatosis in NAFLD. Radiology, 2023, 307, .	3.6	11
454	Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis. World Journal of Gastroenterology, 0, 29, 343-356.	1.4	4
455	Highly Accessible Computational Prediction and In Vivo/In Vitro Experimental Validation: Novel Synthetic Phenyl Ketone Derivatives as Promising Agents against NAFLD via Modulating Oxidoreductase Activity. Oxidative Medicine and Cellular Longevity, 2023, 2023, 1-14.	1.9	2
456	Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. Alimentary Pharmacology and Therapeutics, 2023, 57, 600-609.	1.9	17
457	Application of Caenorhabditis elegans in Lipid Metabolism Research. International Journal of Molecular Sciences, 2023, 24, 1173.	1.8	8
458	Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017-2018. Hepatology Communications, 2023, 7, e0019-e0019.	2.0	5
459	Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. World Journal of Gastroenterology, 0, 29, 286-309.	1.4	2
460	Prevalence and factors associated with liver fibrosis among first-degree relatives of Mexican Americans with hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2023, 57, 378-386.	1.9	7
461	The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multicohort study. Hepatology, 2023, 77, 2063-2072.	3.6	9
462	Natural Foods for the Treatment of Nonalcoholic Fatty Liver Disease. Journal of Medicinal Food, 2023, 26, 1-13.	0.8	1
463	Roles of conventional and complementary therapies in recurrent hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 0, 15, 19-35.	0.8	0
464	Bergamottin reduces liver damage by suppressing inflammation, endoplasmic reticulum and oxidative stress in cafeteria diet-fed mice. Food Bioscience, 2023, 52, 102371.	2.0	1
465	Estimates and trends of the global burden of NASH-related liver cancer attributable to high fasting plasma glucose in 1990-2019: analysis of data from the 2019 Global Burden of Disease Study. Diabetology and Metabolic Syndrome, 2023, 15, .	1.2	4
466	Microbiota and Liver Cancer. , 2023, , 67-90.		1
467	Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice. Free Radical Biology and Medicine, 2023, 195, 199-218.	1.3	7
468	Characteristics and analysis of the costs of drug provision of patients with non-alcoholic fatty liver disease in Moscow. Zdravookhranenie Rossiiskoi Federatsii / Ministerstvo Zdravookhraneniia RSFSR, 2022, 66, 473-477.	0.1	0

#	ARTICLE	IF	CITATIONS
469	Clinical features and management issues of NAFLD-related HCC: what we know so far. <i>Expert Review of Gastroenterology and Hepatology</i> , 2023, 17, 31-43.	1.4	4
470	Extensive Summary of the Important Roles of Indole Propionic Acid, a Gut Microbial Metabolite in Host Health and Disease. <i>Nutrients</i> , 2023, 15, 151.	1.7	19
471	ALS-L1023 from <i>Melissa officinalis</i> Alleviates Liver Fibrosis in a Non-Alcoholic Fatty Liver Disease Model. <i>Life</i> , 2023, 13, 100.	1.1	2
472	Trends of Hepatocellular Carcinoma (HCC) Inpatients Mortality and Financial Burden From 2011 to 2017. <i>Journal of Clinical Gastroenterology</i> , 0, Publish Ahead of Print, .	1.1	1
473	Effect of Metabolic Surgery on Non-Alcoholic Steatohepatitis. , 2023, , 1005-1011.		0
474	ADAM10 Gene Polymorphism and Its Relationship to Hepatocellular Carcinoma in Egyptian HCV Patients Receiving Direct-Acting Antiviral Therapies (DAAs). <i>Asian Pacific Journal of Cancer Prevention</i> , 2023, 24, 149-155.	0.5	0
476	The relationship between NAFLD and retinol-binding protein 4 - an updated systematic review and meta-analysis. <i>Lipids in Health and Disease</i> , 2023, 22, .	1.2	2
477	Multifactorial Diseases of the Heart, Kidneys, Lungs, and Liver and Incident Cancer: Epidemiology and Shared Mechanisms. <i>Cancers</i> , 2023, 15, 729.	1.7	6
478	Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. <i>Nutrients</i> , 2023, 15, 687.	1.7	12
479	Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: The Prognostic Role of Liver Stiffness Measurement. <i>Cancers</i> , 2023, 15, 637.	1.7	1
480	Inflammatory processes involved in NASH-related hepatocellular carcinoma. <i>Bioscience Reports</i> , 2023, 43, .	1.1	8
481	TBC1D25 alleviates nonalcoholic steatohepatitis by inhibiting abnormal lipid accumulation and inflammation. <i>Journal of Cellular Physiology</i> , 0, , .	2.0	2
482	Crosstalk between Gut Microbiota and Host Immunity: Impact on Inflammation and Immunotherapy. <i>Biomedicines</i> , 2023, 11, 294.	1.4	31
483	Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	7
484	The Performance of GALAD Score for Diagnosing Hepatocellular Carcinoma in Patients with Chronic Liver Diseases: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 949.	1.0	9
485	Statin can reduce the risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2023, 35, 353-358.	0.8	6
486	Global Epidemiology and Genetics of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2023, 164, 766-782.	0.6	67
487	Translational Control of Metabolism and Cell Cycle Progression in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4885.	1.8	5

#	ARTICLE	IF	CITATIONS
488	A TNF α /Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2023, 79, 403-416.	1.8	8
489	The Effect of Obesity on Gastrointestinal Disease. <i>Gastroenterology Clinics of North America</i> , 2023, 52, 403-415.	1.0	2
490	Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice. <i>IScience</i> , 2023, 26, 106561.	1.9	0
491	Contrast-Enhanced Imaging Features and Clinicopathological Investigation of Steatohepatic Hepatocellular Carcinoma. <i>Diagnostics</i> , 2023, 13, 1337.	1.3	2
492	The prophylactic treatment of Egyptian, <i>Trigonella foenum - graecum</i> L., Extract in comparison to pure diosgenin on experimentally induced non-alcoholic steatohepatitis: New targets via AMPK, RAR, and FXR pathways. <i>Phytomedicine Plus</i> , 2023, 3, 100421.	0.9	1
493	Identification of potential feature genes in non-alcoholic fatty liver disease using bioinformatics analysis and machine learning strategies. <i>Computers in Biology and Medicine</i> , 2023, 157, 106724.	3.9	4
494	Chlorogenic acid ameliorated non-alcoholic steatohepatitis via alleviating hepatic inflammation initiated by LPS/TLR4/MyD88 signaling pathway. <i>Chemico-Biological Interactions</i> , 2023, 376, 110461.	1.7	5
496	Comparison of Machine Learning Models and the Fatty Liver Index in Predicting Lean Fatty Liver. <i>Diagnostics</i> , 2023, 13, 1407.	1.3	1
497	Laparoscopic Liver Resection: A Tool to Improve Outcomes in Obese Patients Requiring Liver Resection. <i>Open Journal of Gastroenterology</i> , 2022, 12, 347-360.	0.1	0
498	Burden of liver cancer: From epidemiology to prevention. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022, 34, 554-566.	0.7	16
499	Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials. <i>Expert Review of Gastroenterology and Hepatology</i> , 2023, 17, 273-282.	1.4	6
500	Tuning liver pyruvate kinase activity up or down with a new class of allosteric modulators. <i>European Journal of Medicinal Chemistry</i> , 2023, 250, 115177.	2.6	2
502	Effect of Dietary Intervention, with or without Cointerventions, on Inflammatory Markers in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Advances in Nutrition</i> , 2023, 14, 475-499.	2.9	4
503	Bidirectional association between NAFLD and gallstone disease: a systematic review and meta-analysis of observational studies. <i>Expert Review of Gastroenterology and Hepatology</i> , 2023, 17, 283-293.	1.4	3
504	Single-Cell Analysis of Primary Liver Cancer in Mouse Models. <i>Cells</i> , 2023, 12, 477.	1.8	0
505	Nutrient transporters: connecting cancer metabolism to therapeutic opportunities. <i>Oncogene</i> , 2023, 42, 711-724.	2.6	5
506	The Effects of Eight Weeksâ€™ Very Low-Calorie Ketogenic Diet (VLCKD) on Liver Health in Subjects Affected by Overweight and Obesity. <i>Nutrients</i> , 2023, 15, 825.	1.7	10
507	Proto-Oncogene FAM50A Can Regulate the Immune Microenvironment and Development of Hepatocellular Carcinoma In Vitro and In Vivo. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3217.	1.8	2

#	ARTICLE	IF	CITATIONS
508	Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study. <i>European Journal of Internal Medicine</i> , 2023, 110, 62-70.	1.0	4
509	A Multi-Omics Analysis of NASH-Related Prognostic Biomarkers Associated with Drug Sensitivity and Immune Infiltration in Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2023, 12, 1286.	1.0	0
510	Associations between dietary fatty acid patterns and non-alcoholic fatty liver disease in typical dietary population: A UK biobank study. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	2
511	An Angiogenic Gene Signature for Prediction of the Prognosis and Therapeutic Responses of Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3324.	1.8	1
512	<i>In Vivo</i> Imaging of Lipid Droplets and Oxygen Status in Hepatic Tissues of Nonalcoholic Fatty Liver Model Mice Using a Lipophilic Ir(III) Complex. <i>Analytical Chemistry</i> , 2023, 95, 3729-3735.	3.2	3
513	Retrograde regulation of mitochondrial fission and epithelial to mesenchymal transition in hepatocellular carcinoma by GCN5L1. <i>Oncogene</i> , 2023, 42, 1024-1037.	2.6	3
515	Inhibitory Effect of Styrylpyrone Extract of <i>Phellinus linteus</i> on Hepatic Steatosis in HepG2 Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3672.	1.8	0
516	The genetic background shapes the susceptibility to mitochondrial dysfunction and NASH progression. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	13
517	Stationary Trend in Elevated Serum Alpha-Fetoprotein Level in Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2023, 15, 1222.	1.7	2
518	Upregulation of TUBG1 expression promotes hepatocellular carcinoma development. , 2023, 40, .		1
519	Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus. <i>BMJ Open Diabetes Research and Care</i> , 2023, 11, e003066.	1.2	3
520	Management of Hepatocellular Carcinoma. <i>JAMA Surgery</i> , 2023, 158, 410.	2.2	72
521	Association of aspirin with all-cause and cardiocerebrovascular mortality in patients with metabolic associated fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 908-914.	0.6	0
522	Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes. <i>Gut and Liver</i> , 2023, 17, 610-619.	1.4	4
523	Genetic Susceptibility to Hepatocellular Carcinoma in Patients with Chronic Hepatitis Virus Infection. <i>Viruses</i> , 2023, 15, 559.	1.5	6
524	Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease. <i>Cancers</i> , 2023, 15, 1308.	1.7	3
525	Prognosis after hepatic resection of patients with hepatocellular carcinoma related to non-alcoholic fatty liver disease: meta-analysis. <i>BJS Open</i> , 2023, 7, .	0.7	4
526	Ferroptosis-Related Gene SLC1A5 Is a Novel Prognostic Biomarker and Correlates with Immune Microenvironment in HBV-Related HCC. <i>Journal of Clinical Medicine</i> , 2023, 12, 1715.	1.0	2

#	ARTICLE	IF	CITATIONS
527	Fucoidan from <i>Sargassum thunbergii</i> obtained via step gradient ethanol precipitation indicate potential anti-obesity and anti-hepatic steatosis in vitro 3T3-L1 and HepG2 cells and in vivo high-fat diet-induced obesity mice. <i>Food and Chemical Toxicology</i> , 2023, 174, 113686.	1.8	0
528	Clinical effectiveness of L-lipoic acid, myo-inositol and propolis supplementation on metabolic profiles and liver function in obese patients with NAFLD: A randomized controlled clinical trial. <i>Clinical Nutrition ESPEN</i> , 2023, 54, 412-420.	0.5	3
529	Osteoprotegerin deficiency aggravates methionine-choline-deficient diet-induced nonalcoholic steatohepatitis in mice. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
530	Prevalence of non-alcoholic fatty liver disease in patients with nephrotic syndrome: A population-based study. <i>World Journal of Hepatology</i> , 0, 15, 265-273.	0.8	2
532	<i>Clostridioides difficile</i> infection in patients with nonalcoholic fatty liver disease-current status. <i>World Journal of Hepatology</i> , 0, 15, 208-215.	0.8	0
533	Evaluation of Artificial Intelligence-Calculated Hepatorenal Index for Diagnosing Mild and Moderate Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease. <i>Medicina (Lithuania)</i> , 2023, 59, 469.	0.8	3
534	Pathogenesis of NAFLD-Related Hepatocellular Carcinoma: An Up-to-Date Review. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 347-356.	1.8	1
535	Gradual deterioration of fatty liver disease to liver cancer via inhibition of AMPK signaling pathways involved in energy-dependent disorders, cellular aging, and chronic inflammation. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
536	Prognostic Value of Simple Non-Invasive Tests for the Risk Stratification of Incident Hepatocellular Carcinoma in Cirrhotic Individuals with Non-Alcoholic Fatty Liver Disease. <i>Cancers</i> , 2023, 15, 1659.	1.7	3
537	Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 413-428.	1.8	10
538	Nonalcoholic fatty liver disease (NAFLD) detection and deep learning in a Chinese community-based population. <i>European Radiology</i> , 2023, 33, 5894-5906.	2.3	2
539	Ameliorative Effect of <i>Posidonia oceanica</i> on High Glucose-Related Stress in Human Hepatoma HepG2 Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5203.	1.8	1
540	The Multifaceted Roles of Macrophages in NAFLD Pathogenesis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 15, 1311-1324.	2.3	13
541	Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making. <i>Expert Review of Gastroenterology and Hepatology</i> , 2023, 17, 317-324.	1.4	3
542	Prediction of the mechanisms of action of Qutan Huoxue decoction in non-alcoholic steatohepatitis (NASH): a network pharmacology study and experimental validation. <i>Pharmaceutical Biology</i> , 2023, 61, 520-530.	1.3	0
543	Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 404-407.	4.5	2
544	From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications. <i>Biomedicines</i> , 2023, 11, 883.	1.4	14
545	Deregulated bile acids may drive hepatocellular carcinoma metastasis by inducing an immunosuppressive microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2

#	ARTICLE	IF	CITATIONS
546	Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 487-503.	8.2	55
547	LCN2 contributes to the improvement of nonalcoholic steatohepatitis by 8-Cetylberberine. <i>Life Sciences</i> , 2023, 321, 121595.	2.0	0
548	Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	3
549	LncRNA and circRNA in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review. <i>Biomolecules</i> , 2023, 13, 560.	1.8	10
550	Association of Diabetes Mellitus with All-Cause and Cause-Specific Mortality among Patients with Metabolic-Dysfunction-Associated Fatty Liver Disease: A Longitudinal Cohort Study. <i>Journal of Personalized Medicine</i> , 2023, 13, 554.	1.1	0
551	The Association between Advanced Liver Fibrosis and Mortality Is Modified by Dietary Quality among Korean Adults: Results from the Korea National Health and Nutrition Examination Survey with Mortality Data. <i>Nutrients</i> , 2023, 15, 1501.	1.7	0
552	Endocrine disrupting chemicals: A promoter of non-alcoholic fatty liver disease. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	4
553	Alcoholic Liver Disease-Related Hepatocellular Carcinoma: Characteristics and Comparison to General Slovak Hepatocellular Cancer Population. <i>Current Oncology</i> , 2023, 30, 3557-3570.	0.9	1
554	Quantitative proteomics reveals <i>Polygonum perfoliatum</i> L. ameliorates hepatic steatosis by promoting PPARs/CPT1A/CPT2-mediated fatty acid β -oxidation. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
555	Global burden of liver disease: 2023 update. <i>Journal of Hepatology</i> , 2023, 79, 516-537.	1.8	141
556	Splenectomy and azygoportal disconnection decreases the risk of hepatocellular carcinoma for cirrhosis patients with portal hypertension bleeding: a 10-year retrospective follow-up study based on the inverse probability of treatment weighting method. <i>Journal of Gastroenterology</i> , 2023, 58, 503-512.	2.3	2
557	Machine learning integrations develop an antigen-presenting-cells and T-Cells-Infiltration derived LncRNA signature for improving clinical outcomes in hepatocellular carcinoma. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
558	Should we undertake surveillance for HCC in patients with MAFLD?. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2023, 14, 204201882311603.	1.4	1
559	Global epidemiology of cirrhosis – aetiology, trends and predictions. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 388-398.	8.2	82
560	Ein beunruhigender Trend. , 2023, , 13-27.		0
561	Unravelling the role of obesity and lipids during tumor progression. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
562	LIPOSOMAL TECHNOLOGIES FOR SILYBIN DELIVERY TO THE LIVER IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Ulyanovsk Medico-biological Journal</i> , 2023, , 50-62.	0.0	0
563	The Role of Ablative Techniques in the Management of Hepatocellular Carcinoma: Indications and Outcomes. <i>Biomedicines</i> , 2023, 11, 1062.	1.4	2

#	ARTICLE	IF	CITATIONS
564	Membrane phospholipid remodeling modulates nonalcoholic steatohepatitis progression by regulating mitochondrial homeostasis. <i>Hepatology</i> , 0, Publish Ahead of Print, .	3.6	5
565	Association between nonalcoholic fatty liver disease and atrial fibrillation and other clinical outcomes: a meta-analysis. <i>Journal of Investigative Medicine</i> , 2023, 71, 591-602.	0.7	5
567	Associations between an inflammatory diet index and severe non-alcoholic fatty liver disease: a prospective study of 171,544 UK Biobank participants. <i>BMC Medicine</i> , 2023, 21, .	2.3	13
568	Silymarin for treatment of adults with nonalcoholic fatty liver disease. <i>The Cochrane Library</i> , 2023, .	1.5	0
569	Fatty Liver Disease. , 2024, , 330-401.		1
570	WNT/ β -catenin signaling in hepatocellular carcinoma: The aberrant activation, pathogenic roles, and therapeutic opportunities. <i>Genes and Diseases</i> , 2024, 11, 727-746.	1.5	6
571	Effect of vessels that encapsulate tumor clusters (VETC) on the prognosis of different stages of hepatocellular carcinoma after hepatectomy. <i>Digestive and Liver Disease</i> , 2023, 55, 1288-1294.	0.4	2
572	Fatty Liver Disease in Patients with Prediabetes and Overweight or Obesity. <i>Metabolites</i> , 2023, 13, 531.	1.3	1
573	CD73, a significant protein in liver diseases. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	1
575	High Prevalence of Severe Hepatic Fibrosis in Type 2 Diabetic Outpatients Screened for Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2023, 12, 2858.	1.0	1
576	Thymidine kinase 1 drives hepatocellular carcinoma in enzyme-dependent and -independent manners. <i>Cell Metabolism</i> , 2023, 35, 912-927.e7.	7.2	3
577	The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories. <i>Hepatology</i> , 2023, 78, 911-928.	3.6	6
578	Identification of Hub Genes and Immune Infiltration in Non-alcoholic Fatty Liver Disease -Related Hepatocellular Carcinoma by Bioinformatics Analysis. , 2023, 34, 383-393.		0
579	Non-alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma. , 0, , .		0
580	Is fatigue related to the severity of liver inflammation in patients with chronic liver disease? A cross-sectional study. <i>BMJ Open</i> , 2023, 13, e069028.	0.8	0
581	Alterations in Cytoskeleton and Mitochondria in the Development and Reversal of Steatosis in Human Hepatocytes. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 16, 243-261.	2.3	2
582	Histone Demethylation Profiles in Nonalcoholic Fatty Liver Disease and Prognostic Values in Hepatocellular Carcinoma: A Bioinformatic Analysis. <i>Current Issues in Molecular Biology</i> , 2023, 45, 3640-3657.	1.0	1
583	Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective. <i>Nutrients</i> , 2023, 15, 1992.	1.7	3

#	ARTICLE	IF	CITATIONS
601	Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 679-688.	8.2	17
653	Semi-automatic Approach to Estimate the Degree of Non-alcoholic Fatty Liver Disease (NAFLD) from Ultrasound Images. <i>IFMBE Proceedings</i> , 2023, , 227-235.	0.2	0
662	MAFLD: an optimal framework for understanding liver cancer phenotypes. <i>Journal of Gastroenterology</i> , 2023, 58, 947-964.	2.3	3
668	Information Entropy and Its Applications. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 153-167.	0.8	0
672	Hepatocellular carcinoma surveillance “utilization, barriers and the impact of changing aetiology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 797-809.	8.2	12
679	Friend or foe? The elusive role of hepatic stellate cells in liver cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 647-661.	8.2	11
681	The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 764-783.	8.2	15
693	Biomarkers for immunotherapy of hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 780-798.	12.5	5
707	<i>Cancer Epidemiology</i> , 2023, , 1-43.		0